Earnings Call Summary1. Fully funded into Q1 2023 2. Only allowed to dilute 1/3 of market cap per year. 3. Extremely excited about THCV with has potential weight loss applications 4. 3 separate analysts with very knowledgeable questions. 5. Garnering interest and having meetings with people through the DERM program about pre-clinical partnering in the ocular space. 6. Acknowledged the tough few months related to share price. 7. 14.1 million shares outstanding. No change since July 2020.